The Melanoma Research Alliance (“MRA”) announced today that Wendy Selig has informed its Board of Directors of her plan to step down as President and CEO, posts she has held for the past five years, in order to establish a new consulting venture. Ms. Selig will remain to assist MRA through the transition over the next few months.
Debra Black, a founder and chair of MRA, expressed her and the Board’s appreciation for the contributions Ms. Selig has made during the time she headed MRA, which is dedicated to funding research into the treatment and cures for melanoma, a skin disease that is one of the fastest growing cancers.
“Wendy importantly helped oversee and develop the growth of MRA almost from the start into its becoming the leading private funder of melanoma research worldwide with more than $60 million in cutting edge research grants across 14 countries. We are greatly appreciative and wish Wendy the best of luck in her new endeavor,” said Ms. Black.
Ms. Black also reported that Ms. Selig will continue an association with MRA as a consultant. A search for her replacement is currently underway, she added.
Ms. Selig said that she remains deeply committed to the mission of MRA. “It has been an honor and privilege to work with MRA’s founders, Debra and Leon Black, its Board and the leadership of the Milken Institute, under whose auspices MRA was launched and remains, in making MRA the premier non-profit organization in the field of melanoma research,” she said. “My tenure at MRA has been remarkable with tremendous progress made for patients, and I am excited to continue to be engaged with MRA with my new venture, WSCollaborative, which will provide a platform to advance many of the same successful models of cross-sector collaboration we pioneered at MRA.”
About the Melanoma Research Alliance
MRA is a public charity formed in 2007 under the auspices of the Milken Institute, with the generous founding support of Debra and Leon Black. MRA has dedicated more than $60 million to research seeking to better prevent, diagnose, and treat melanoma, the most deadly type of skin cancer. Due to the ongoing support of its founders, 100% of every dollar MRA raises goes to support its melanoma research program. The organization is poised to build on recent momentum in the field, accelerating the pace of scientific discovery and translation in order to eliminate suffering and death due to melanoma. MRA’s ability to fund wide-ranging research in melanoma is amplified by unique multi-faceted collaborations and partnerships with individuals, private foundations, and corporations. For more information, please visit www.CureMelanoma.org.
Copyright © 2018 CancerConnect. All Rights Reserved.